問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Radiation Therapy

Division of General Surgery

Division of General Internal Medicine

Division of Hematology & Oncology

Digestive System Department

Linkou Chang Gung Medical Foundation (在職)

Division of Hematology & Oncology

更新時間：2023-09-19

陳彥仰
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

65Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳彥仰

List

158Cases

2025-02-03 - 2029-12-23

Not yet recruiting
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of TPST-1120 in Combination With Atezolizumab Plus Bevacizumab Compared With Placebo Plus Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma (HCC) Not Previously Treated With Systemic Therapy

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    TPST-1120

Participate Sites
6Sites

Recruiting6Sites

2025-03-01 - 2030-02-01

Phase III

Active
A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab Versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-Line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric Or Gastroesophageal Junction (GEJ) Cancer (Destiny-Gastric05)

  • Condition/Disease

    Gastric Cancer 、Gastroesophageal Junction Cancer

  • Test Drug

    Frozen Crystal Injection Frozen Crystal Injection Injection Injection Injection Film-Coated Tablets Injection

Participate Sites
5Sites

Recruiting5Sites

2025-04-01 - 2030-06-18

Phase III

Active
A Phase III, Randomised, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    Injectables Injectables Injectables

Participate Sites
8Sites

Recruiting8Sites

2025-11-07 - 2029-09-25

Phase III

Not yet recruiting
Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02)

  • Condition/Disease

    Biliary Tract Cancer

  • Test Drug

    Injectables

Participate Sites
8Sites

Recruiting8Sites

2016-06-01 - 2024-06-28

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated6Sites

莊正鏗
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2012-11-30 - 2017-06-30

Phase IV

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2025-09-01 - 2027-05-31

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2023-01-01 - 2028-11-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Recruiting13Sites

2009-10-15 - 2011-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2005-11-01 - 2008-01-01

Others

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

1 2 3 4 5 16
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB